Mohan, Vignes; Schönhofen, Jan; Hoppe, Hanno; Schumacher, Martin; Keo, Hak-Hong; Bechir, Markus; Kalka, Christoph; Burkhard Rn, Madlen; Diehm, Nicolas (2023). Long-Term Outcomes of Drug-Eluting Stent Implantation for Patients With Atherosclerotic Erectile Dysfunction not Responding to PDE-5-Inhibitors. (In Press). Journal of endovascular therapy(15266028231183775), p. 15266028231183775. Sage 10.1177/15266028231183775
Full text not available from this repository. (Request a copy)PURPOSE
Endovascular therapy of erection-related arteries was shown to be a promising treatment option for patients with severe erectile dysfunction. Purpose of this study was to assess the longer-term safety and clinical success rate of endovascular revascularization of erection-related arteries with the Angiolite BTK stent in patients with arteriogenic erectile dysfunction.
MATERIALS AND METHODS
A total of 147 consecutive men (63.5±9.3 years) with erectile dysfunction due to 345 atherosclerotic lesions underwent endovascular revascularization. Patients received an International Index of Erectile Function (IIEF)-15 questionnaire at 30.3±7.2 months (follow-up [FU] period no less than 18 months) after stenting. An improvement by 4 points in the erectile function domain consisting of 6 questions (IIEF-6) was defined as minimal clinically important difference (MCID).
RESULTS
Technical success was achieved in 99% of lesions. One major adverse event occurred after endovascular revascularization. Sixty-eight (46%) patients completed their latest FU at least 18 months following the last intervention. Minimal clinically important difference was achieved in 54% (37/68) of patients.
CONCLUSIONS
In patients with arteriogenic erectile dysfunction not responding to phosphodiesterase-5-inhibitors (PDE-5-Is), endovascular therapy with a novel thin-strut sirolimus-eluting stent is a safe and effective treatment option during short- and longer-term FU.
CLINICAL IMPACT
Patients with severe erectile dysfunction profit greatly from endovascular therapy of erection-related arteries. Stable clinical outcomes are seen beyond a 1-year timeframe. It is proven that, the drug-eluting stent therapy for atherosclerotic ED in patients who have not responded to PDE-5-I therapy is safe and effective during longer-term follow-up.
Item Type: |
Journal Article (Original Article) |
|---|---|
UniBE Contributor: |
Hoppe, Hanno, Diehm, Nicolas Alexander |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1545-1550 |
Publisher: |
Sage |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
27 Jun 2023 15:14 |
Last Modified: |
28 Jun 2023 00:17 |
Publisher DOI: |
10.1177/15266028231183775 |
PubMed ID: |
37365869 |
Uncontrolled Keywords: |
PDE-5-inhibitors drug-eluting stent erection pudendal |
URI: |
https://boris.unibe.ch/id/eprint/184179 |
Actions (login required)
 |
Edit item |